Bihua Chen - Net Worth and Insider Trading

Bihua Chen Net Worth

The estimated net worth of Bihua Chen is at least $614 Million dollars as of 2026-09-11. Bihua Chen is the Former 10% Owner of MoonLake Immunotherapeutics and owns about 25,408,519 shares of MoonLake Immunotherapeutics (MLTX) stock worth over $335 Million. Bihua Chen is the Director of Erasca Inc and owns about 10,813,246 shares of Erasca Inc (ERAS) stock worth over $173 Million. Bihua Chen is also the Director, 10% Owner of BlossomHill Therapeutics Inc and owns about 3,614,034 shares of BlossomHill Therapeutics Inc (BLSM) stock worth over $78 Million. Besides these, Bihua Chen also holds Helix Acquisition Corp III (HLXC) , Helix Acquisition Corp II (HLXB) , Helix Acquisition Corp (HLXA) . Details can be seen in Bihua Chen's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Bihua Chen has not made any transactions after 2026-08-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Bihua Chen

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

MLTX MoonLake Immunotherapeutics

56% of holdings · $348.6M

27% of holdings · $169.8M

BLSM BlossomHill Therapeutics Inc

13% of holdings · $79.5M

HLXC Helix Acquisition Corp III

2% of holdings · $14.0M

HLXA Helix Acquisition Corp

1% of holdings · $5.7M

Bihua Chen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Bihua Chen owns 47 companies in total, including Helix Acquisition Corp (HLXA) , Akouos Inc (AKUS) , and Avidity Biosciences Inc (RNAM) among others .

Click here to see the complete history of Bihua Chen’s form 4 insider trades.

Insider Ownership Summary of Bihua Chen

Ticker	Company	Transaction Date	Type of Owner
HLXA	Helix Acquisition Corp	2020-10-22	director & 10 percent owner & CEO and Chairman
AKUS	Akouos Inc	2020-06-25	director & 10 percent owner
RNAM	Avidity Biosciences Inc	2020-06-11	director & 10 percent owner
		2019-04-22	director & 10 percent owner
		2018-10-30	director & 10 percent owner
		2018-07-18	director & 10 percent owner
		2018-06-20	director & 10 percent owner
		2018-05-23	director & 10 percent owner
		2017-12-14	director & 10 percent owner
		2017-11-08	director & 10 percent owner
		2016-06-01	director & 10 percent owner
		2014-08-15	director & 10 percent owner
		2016-11-03	director & 10 percent owner
		2020-10-29	director & 10 percent owner
		2021-03-11	director & 10 percent owner
		2021-04-22	director & 10 percent owner
		2020-11-18	director & 10 percent owner
		2022-12-20	director
		2021-10-07	10 percent owner
		2021-06-24	10 percent owner
		2021-07-28	10 percent owner
		2023-04-20	10 percent owner
		2021-06-29	10 percent owner
		2021-03-25	director & 10 percent owner
		2025-09-30	10 percent owner
		2021-06-23	director & 10 percent owner
		2020-12-15	director & 10 percent owner
		2022-01-06	10 percent owner
		2023-03-30	director & 10 percent owner
		2021-06-16	director & 10 percent owner
		2021-10-20	10 percent owner
		2021-09-14	10 percent owner
		2016-11-03	director & 10 percent owner
		2023-03-03	10 percent owner
		2023-05-29	other: See below
		2023-05-29	other: See below
		2023-10-23	10 percent owner
		2024-10-04	10 percent owner
		2023-12-04	10 percent owner
		2024-01-26	10 percent owner
		2024-09-25	10 percent owner
		2025-02-12	10 percent owner
		2021-06-29	10 percent owner
		2024-10-15	10 percent owner
		2024-02-08	director & 10 percent owner
		2026-01-22	director & 10 percent owner & Chairperson and CEO
		2026-08-06	director & 10 percent owner

Bihua Chen Latest Holdings Summary

Bihua Chen currently owns a total of 6 stocks. Among these stocks, Bihua Chen owns 25,408,519 shares of MoonLake Immunotherapeutics (MLTX) as of September 30, 2025, with a value of $335 Million and a weighting of 54.46%. Bihua Chen owns 10,813,246 shares of Erasca Inc (ERAS) as of December 13, 2022, with a value of $173 Million and a weighting of 28.23%. Bihua Chen also owns 3,614,034 shares of BlossomHill Therapeutics Inc (BLSM) as of August 10, 2026, with a value of $78 Million and a weighting of 12.65%. The other 3 stocks Helix Acquisition Corp III (HLXC) , Helix Acquisition Corp II (HLXB) , Helix Acquisition Corp (HLXA) have a combined weighting of 4.67% among all his current holdings.

Latest Holdings of Bihua Chen

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MLTX	MoonLake Immunotherapeutics	2025-09-30	25,408,519	13.17	334,630,195
ERAS	Erasca Inc	2022-12-13	10,813,246	16.04	173,444,466
BLSM	BlossomHill Therapeutics Inc	2026-08-10	3,614,034	21.51	77,737,871
HLXC	Helix Acquisition Corp III	2026-01-26	1,297,500	10.80	14,013,000
HLXB	Helix Acquisition Corp II	2024-02-13	903,600	9.93	8,972,748
HLXA	Helix Acquisition Corp	2020-10-22	430,000	13.25	5,697,500

Holding Weightings of Bihua Chen

Bihua Chen Form 4 Trading Tracker

According to the SEC Form 4 filings, Bihua Chen has made a total of 6 transactions in MoonLake Immunotherapeutics (MLTX) over the past 5 years, including 5 buys and 1 sells. The most-recent trade in MoonLake Immunotherapeutics is the sale of 6,499,978 shares on September 30, 2025, which brought Bihua Chen around $47 Million.

According to the SEC Form 4 filings, Bihua Chen has made a total of 2 transactions in Erasca Inc (ERAS) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Erasca Inc is the acquisition of 307,692 shares on December 13, 2022, which cost Bihua Chen around $2 Million.

According to the SEC Form 4 filings, Bihua Chen has made a total of 1 transactions in BlossomHill Therapeutics Inc (BLSM) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in BlossomHill Therapeutics Inc is the acquisition of 312,500 shares on August 10, 2026, which cost Bihua Chen around $5 Million.

More details on Bihua Chen's insider transactions can be found in the Insider Trading History of Bihua Chen table.

Insider Trading History of Bihua Chen

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Bihua Chen Trading Performance

GuruFocus tracks the stock performance after each of Bihua Chen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bihua Chen is -4.67%. GuruFocus also compares Bihua Chen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Bihua Chen within 3 months outperforms 2 times out of 10 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Bihua Chen's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Bihua Chen

Average Return

Average return per transaction

Outperforming Transactions

2 out of 9 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	0.62
Relative Return to S&P 500(%)	-1.01

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Bihua Chen owns.

- MLTX - ERAS - BLSM - HLXC - HLXA

View MLTX Analysis

Bihua Chen Ownership Network

Ownership Network List of Bihua Chen

No Data

Ownership Network Relation of Bihua Chen

Bihua Chen Owned Company Details

What does Helix Acquisition Corp do?

Who are the key executives at Helix Acquisition Corp?

Bihua Chen is the director & 10 percent owner & CEO and Chairman of Helix Acquisition Corp. Other key executives at Helix Acquisition Corp include director & 10 percent owner Helix Holdings Llc , and Chief Financial Officer Jay Scollins .

Helix Acquisition Corp (HLXA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Helix Acquisition Corp (HLXA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Helix Acquisition Corp (HLXA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Helix Acquisition Corp (HLXA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Helix Acquisition Corp Insider Transactions

No Available Data

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Bihua Chen is the director & 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akouos Inc Insider Transactions

No Available Data

What does Avidity Biosciences Inc do?

Who are the key executives at Avidity Biosciences Inc?

Bihua Chen is the director & 10 percent owner of Avidity Biosciences Inc. Other key executives at Avidity Biosciences Inc include Chief Financial Officer Michael F Maclean , Chief Medical Officer Steven George Hughes , and Chief Scientific Officer W. Michael Flanagan .

Avidity Biosciences Inc (RNAM) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Avidity Biosciences Inc (RNAM). Other recent insider transactions involving Avidity Biosciences Inc (RNAM) include a net sale of 107,989 shares made by Steven George Hughes , a net sale of 57,672 shares made by Teresa Mccarthy , and a net sale of 129,503 shares made by Sarah Boyce .

In summary, during the past 3 months, insiders sold 0 shares of Avidity Biosciences Inc (RNAM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 806,030 shares of Avidity Biosciences Inc (RNAM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 806,030 shares.

Avidity Biosciences Inc (RNAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avidity Biosciences Inc Insider Transactions

No Available Data

What does Turning Point Therapeutics Inc do?

Who are the key executives at Turning Point Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Turning Point Therapeutics Inc. Other key executives at Turning Point Therapeutics Inc include EVP & Chief Financial Officer Paolo Tombesi , SVP & Chief Commercial Officer Steve M Sabus , and SVP & General Counsel Brian Sun .

Turning Point Therapeutics Inc (TPTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Turning Point Therapeutics Inc (TPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Turning Point Therapeutics Inc (TPTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Turning Point Therapeutics Inc (TPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Turning Point Therapeutics Inc Insider Transactions

No Available Data

What does Axonics Inc do?

Who are the key executives at Axonics Inc?

Bihua Chen is the director & 10 percent owner of Axonics Inc. Other key executives at Axonics Inc include Chief Financial Officer Kari Leigh Keese , Chief Medical Officer Karen Noblett , and director & Chief Executive Officer Raymond W Cohen .

Axonics Inc (AXNX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Axonics Inc (AXNX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Axonics Inc (AXNX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Axonics Inc (AXNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Axonics Inc Insider Transactions

No Available Data

What does Constellation Pharmaceuticals Inc do?

Who are the key executives at Constellation Pharmaceuticals Inc?

Bihua Chen is the director & 10 percent owner of Constellation Pharmaceuticals Inc. Other key executives at Constellation Pharmaceuticals Inc include Chief Financial Officer Emma Reeve , 10 percent owner Column Group L P , and See Remarks Karen Valentine .

Constellation Pharmaceuticals Inc (CNST) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Constellation Pharmaceuticals Inc (CNST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Constellation Pharmaceuticals Inc (CNST) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Constellation Pharmaceuticals Inc (CNST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Constellation Pharmaceuticals Inc Insider Transactions

No Available Data

What does Kezar Life Sciences Inc do?

Who are the key executives at Kezar Life Sciences Inc?

Bihua Chen is the director & 10 percent owner of Kezar Life Sciences Inc. Other key executives at Kezar Life Sciences Inc include SVP & Clinical Development Zung Phoung To , SVP & Corporate Controller Pichi Luo Chiang , and Chief Legal Officer Mark C. Schiller .

Kezar Life Sciences Inc (KZR) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Kezar Life Sciences Inc (KZR). Other recent insider transactions involving Kezar Life Sciences Inc (KZR) include a net sale of 561 shares made by Mark C. Schiller , and a net sale of 264 shares made by Pichi Luo Chiang .

In summary, during the past 3 months, insiders sold 0 shares of Kezar Life Sciences Inc (KZR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 825 shares of Kezar Life Sciences Inc (KZR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 825 shares.

Kezar Life Sciences Inc (KZR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kezar Life Sciences Inc Insider Transactions

No Available Data

What does Kiniksa Pharmaceuticals International PLC do?

Who are the key executives at Kiniksa Pharmaceuticals International PLC?

Bihua Chen is the director & 10 percent owner of Kiniksa Pharmaceuticals International PLC. Other key executives at Kiniksa Pharmaceuticals International PLC include Chief Accounting Officer Michael R Megna , CHIEF STRATEGY OFFICER Dhiraj H Malkani , and director & 10 percent owner & Chairman & CEO Sanj K Patel .

Kiniksa Pharmaceuticals International PLC (KNSA) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Kiniksa Pharmaceuticals International PLC (KNSA). Other recent insider transactions involving Kiniksa Pharmaceuticals International PLC (KNSA) include a net sale of 495,118 shares made by Eben Tessari , a net sale of 327,650 shares made by Mark Ragosa , and a net sale of 921,737 shares made by Sanj K Patel .

In summary, during the past 3 months, insiders sold 8,273 shares of Kiniksa Pharmaceuticals International PLC (KNSA) in total and bought 0 shares, with a net sale of 8,273 shares. During the past 18 months, 2,505,236 shares of Kiniksa Pharmaceuticals International PLC (KNSA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 2,505,236 shares.

Kiniksa Pharmaceuticals International PLC (KNSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kiniksa Pharmaceuticals International PLC Insider Transactions

No Available Data

What does Proteostasis Therapeutics Inc do?

Who are the key executives at Proteostasis Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Proteostasis Therapeutics Inc. Other key executives at Proteostasis Therapeutics Inc include Interim Head of Finance Michael Alfieri , director & President and CEO Meenu Chhabra , and See Remarks Eric D Larson .

Proteostasis Therapeutics Inc (PTI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Proteostasis Therapeutics Inc (PTI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Proteostasis Therapeutics Inc (PTI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Proteostasis Therapeutics Inc (PTI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Proteostasis Therapeutics Inc Insider Transactions

No Available Data

What does Apellis Pharmaceuticals Inc do?

Who are the key executives at Apellis Pharmaceuticals Inc?

Bihua Chen is the director & 10 percent owner of Apellis Pharmaceuticals Inc. Other key executives at Apellis Pharmaceuticals Inc include other: See footnotes Biogen Inc. , Senior Vice President Mark Jeffrey Delong , and General Counsel David O. Watson .

Apellis Pharmaceuticals Inc (APLS) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Apellis Pharmaceuticals Inc (APLS). Other recent insider transactions involving Apellis Pharmaceuticals Inc (APLS) include a net sale of 71,087 shares made by David O. Watson , a net sale of 429,650 shares made by Cedric Francois , and a net sale of 69,764 shares made by Timothy Eugene Sullivan .

In summary, during the past 3 months, insiders sold 0 shares of Apellis Pharmaceuticals Inc (APLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 704,024 shares of Apellis Pharmaceuticals Inc (APLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 704,024 shares.

Apellis Pharmaceuticals Inc (APLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Apellis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Clearside Biomedical Inc do?

Who are the key executives at Clearside Biomedical Inc?

Bihua Chen is the director & 10 percent owner of Clearside Biomedical Inc. Other key executives at Clearside Biomedical Inc include director & 10 percent owner Clay Thorp , CHIEF MEDICAL OFFICER Chong Ngai Hang Victor , and 10 percent owner Bradford T Whitmore .

Clearside Biomedical Inc (CLSDQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Clearside Biomedical Inc (CLSDQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Clearside Biomedical Inc (CLSDQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Clearside Biomedical Inc (CLSDQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Clearside Biomedical Inc Insider Transactions

No Available Data

What does Cellectar Biosciences Inc do?

Who are the key executives at Cellectar Biosciences Inc?

Bihua Chen is the director & 10 percent owner of Cellectar Biosciences Inc. Other key executives at Cellectar Biosciences Inc include Chief Business Officer Jarrod Longcor , director & President and CEO James V Caruso , and Chief Financial Officer Chad J Kolean .

Cellectar Biosciences Inc (CLRB) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Cellectar Biosciences Inc (CLRB). Other recent insider transactions involving Cellectar Biosciences Inc (CLRB) include a net purchase of 18,680 shares made by Jarrod Longcor , a net purchase of 18,680 shares made by James V Caruso , and a net purchase of 5,000 shares made by Chad J Kolean .

In summary, during the past 3 months, insiders sold 0 shares of Cellectar Biosciences Inc (CLRB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 198 shares of Cellectar Biosciences Inc (CLRB) were sold and 42,360 shares were bought by its insiders, resulting in a net purchase of 42,162 shares.

Cellectar Biosciences Inc (CLRB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cellectar Biosciences Inc Insider Transactions

No Available Data

What does Yumanity Therapeutics Inc do?

Who are the key executives at Yumanity Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Yumanity Therapeutics Inc. Other key executives at Yumanity Therapeutics Inc include director & Chief Executive Officer Shawn Iadonato , Chief Scientific Officer Thierry Guillaudeux , and Chief Financial Officer Keith Baker .

Yumanity Therapeutics Inc (YMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Yumanity Therapeutics Inc (YMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Yumanity Therapeutics Inc (YMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Yumanity Therapeutics Inc (YMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Yumanity Therapeutics Inc Insider Transactions

No Available Data

What does Atea Pharmaceuticals Inc do?

Who are the key executives at Atea Pharmaceuticals Inc?

Bihua Chen is the director & 10 percent owner of Atea Pharmaceuticals Inc. Other key executives at Atea Pharmaceuticals Inc include director & 10 percent owner & President & CEO & and Chairman Jean-pierre Sommadossi , See Remarks Andrea Corcoran , and See Remarks Wayne Foster .

Atea Pharmaceuticals Inc (AVIR) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Atea Pharmaceuticals Inc (AVIR). Other recent insider transactions involving Atea Pharmaceuticals Inc (AVIR) include a net purchase of 6,100 shares made by Polly A. Murphy ,

In summary, during the past 3 months, insiders sold 0 shares of Atea Pharmaceuticals Inc (AVIR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Atea Pharmaceuticals Inc (AVIR) were sold and 6,100 shares were bought by its insiders, resulting in a net purchase of 6,100 shares.

Atea Pharmaceuticals Inc (AVIR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Atea Pharmaceuticals Inc Insider Transactions

No Available Data

What does Prometheus Biosciences Inc do?

Who are the key executives at Prometheus Biosciences Inc?

Bihua Chen is the director & 10 percent owner of Prometheus Biosciences Inc. Other key executives at Prometheus Biosciences Inc include Chief Financial Officer Keith W Marshall , director & President and CEO Mark C. Mckenna , and 10 percent owner Cedars Sinai Intellectual Property Co .

Prometheus Biosciences Inc (RXDX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Prometheus Biosciences Inc (RXDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Prometheus Biosciences Inc (RXDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Prometheus Biosciences Inc (RXDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Prometheus Biosciences Inc Insider Transactions

No Available Data

What does Rain Oncology Inc do?

Who are the key executives at Rain Oncology Inc?

Bihua Chen is the director & 10 percent owner of Rain Oncology Inc. Other key executives at Rain Oncology Inc include 10 percent owner Kevin C Tang , Principal Fin. & Acc. Officer Josephine Bruce , and 10 percent owner Tang Capital Management Llc .

Rain Oncology Inc (RAIN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Rain Oncology Inc (RAIN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Rain Oncology Inc (RAIN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Rain Oncology Inc (RAIN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rain Oncology Inc Insider Transactions

No Available Data

What does Olema Pharmaceuticals inc do?

Who are the key executives at Olema Pharmaceuticals inc?

Bihua Chen is the director & 10 percent owner of Olema Pharmaceuticals inc. Other key executives at Olema Pharmaceuticals inc include CHIEF FINANCIAL OFFICER Jason O'byrne , director & Chief Technology Officer Cyrus Harmon , and CHIEF LEGAL OFFICER Shawnte Mitchell .

Olema Pharmaceuticals inc (OLMA) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Olema Pharmaceuticals inc (OLMA). Other recent insider transactions involving Olema Pharmaceuticals inc (OLMA) include a net sale of 66,370 shares made by Cyrus Harmon , a net sale of 161,000 shares made by David C. Myles , and a net sale of 269,509 shares made by Naseem Zojwalla .

In summary, during the past 3 months, insiders sold 25,000 shares of Olema Pharmaceuticals inc (OLMA) in total and bought 0 shares, with a net sale of 25,000 shares. During the past 18 months, 640,701 shares of Olema Pharmaceuticals inc (OLMA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 640,701 shares.

Olema Pharmaceuticals inc (OLMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Olema Pharmaceuticals inc Insider Transactions

No Available Data

What does Erasca Inc do?

Who are the key executives at Erasca Inc?

Bihua Chen is the director of Erasca Inc. Other key executives at Erasca Inc include President & R&D Charles S. Fuchs , General Counsel Ebun Garner , and Chief Medical Officer Shannon Morris .

Erasca Inc (ERAS) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Erasca Inc (ERAS). Other recent insider transactions involving Erasca Inc (ERAS) include a net sale of 80,000 shares made by Ebun Garner , and a net sale of 20,000 shares made by Shannon Morris .

In summary, during the past 3 months, insiders sold 0 shares of Erasca Inc (ERAS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 100,000 shares of Erasca Inc (ERAS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 100,000 shares.

Erasca Inc (ERAS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Erasca Inc Insider Transactions

No Available Data

What does Pyxis Oncology Inc do?

Who are the key executives at Pyxis Oncology Inc?

Bihua Chen is the 10 percent owner of Pyxis Oncology Inc. Other key executives at Pyxis Oncology Inc include 10 percent owner Craig D Gordon , 10 percent owner Gordonmd Long Biased Master Fund Lp , and 10 percent owner Gordonmd Long Biased Gp Llc .

Pyxis Oncology Inc (PYXS) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Pyxis Oncology Inc (PYXS). Other recent insider transactions involving Pyxis Oncology Inc (PYXS) include a net sale of 35,000 shares made by Jakob Dupont , and a net sale of 15,496 shares made by Rachel Humphrey .

In summary, during the past 3 months, insiders sold 35,000 shares of Pyxis Oncology Inc (PYXS) in total and bought 0 shares, with a net sale of 35,000 shares. During the past 18 months, 50,496 shares of Pyxis Oncology Inc (PYXS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 50,496 shares.

Pyxis Oncology Inc (PYXS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pyxis Oncology Inc Insider Transactions

No Available Data

What does Elevation Oncology Inc do?

Who are the key executives at Elevation Oncology Inc?

Bihua Chen is the 10 percent owner of Elevation Oncology Inc. Other key executives at Elevation Oncology Inc include CHIEF FINANCIAL OFFICER Tammy Furlong , 10 percent owner Venbio Global Strategic Gp Iii, L.p. , and 10 percent owner Venbio Global Strategic Fund Iii, L.p. .

Elevation Oncology Inc (ELEV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Elevation Oncology Inc (ELEV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Elevation Oncology Inc (ELEV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Elevation Oncology Inc (ELEV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Elevation Oncology Inc Insider Transactions

No Available Data

What does Icosavax Inc do?

Who are the key executives at Icosavax Inc?

Bihua Chen is the 10 percent owner of Icosavax Inc. Other key executives at Icosavax Inc include director & Chief Executive Officer Adam K. Simpson , Chief Medical Officer Niranjan Kanesa-thasan , and Chief Financial Officer Thomas Joseph Russo .

Icosavax Inc (ICVX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Icosavax Inc (ICVX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Icosavax Inc (ICVX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Icosavax Inc (ICVX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Icosavax Inc Insider Transactions

No Available Data

What does Immuneering Corp do?

Who are the key executives at Immuneering Corp?

Bihua Chen is the 10 percent owner of Immuneering Corp. Other key executives at Immuneering Corp include Chief Financial Officer Andrew Gengos , director & 10 percent owner & President and CEO Benjamin J. Zeskind , and Chief Scientific Officer Brett Matthew Hall .

Immuneering Corp (IMRX) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Immuneering Corp (IMRX). Other recent insider transactions involving Immuneering Corp (IMRX) include a net purchase of 65,000 shares made by Peter Feinberg , a net purchase of 71,630 shares made by Thomas J. Schall , and a net purchase of 33,400 shares made by Benjamin J. Zeskind .

In summary, during the past 3 months, insiders sold 0 shares of Immuneering Corp (IMRX) in total and bought 8,435 shares, with a net purchase of 8,435 shares. During the past 18 months, 0 shares of Immuneering Corp (IMRX) were sold and 209,881 shares were bought by its insiders, resulting in a net purchase of 209,881 shares.

Immuneering Corp (IMRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immuneering Corp Insider Transactions

No Available Data

What does Aerovate Therapeutics Inc do?

Who are the key executives at Aerovate Therapeutics Inc?

Bihua Chen is the 10 percent owner of Aerovate Therapeutics Inc. Other key executives at Aerovate Therapeutics Inc include director & 10 percent owner Ra Capital Healthcare Fund Lp , See Remarks George A Eldridge , and SENIOR VICE PRESIDENT & CMC Marinus Verwijs .

Aerovate Therapeutics Inc (AVTE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aerovate Therapeutics Inc (AVTE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aerovate Therapeutics Inc (AVTE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aerovate Therapeutics Inc (AVTE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerovate Therapeutics Inc Insider Transactions

No Available Data

What does Design Therapeutics Inc do?

Who are the key executives at Design Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Design Therapeutics Inc. Other key executives at Design Therapeutics Inc include Chief Medical Officer Chris Storgard , 10 percent owner Dunham Trust Co , and Chief Medical Officer Jae B. Kim .

Design Therapeutics Inc (DSGN) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Design Therapeutics Inc (DSGN). Other recent insider transactions involving Design Therapeutics Inc (DSGN) include a net sale of 562,627 shares made by Arsani William ,

In summary, during the past 3 months, insiders sold 0 shares of Design Therapeutics Inc (DSGN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 562,627 shares of Design Therapeutics Inc (DSGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 562,627 shares.

Design Therapeutics Inc (DSGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Design Therapeutics Inc Insider Transactions

No Available Data

What does MoonLake Immunotherapeutics do?

Who are the key executives at MoonLake Immunotherapeutics?

Bihua Chen is the 10 percent owner of MoonLake Immunotherapeutics. Other key executives at MoonLake Immunotherapeutics include Chief Scientific Officer Kristian Reich , director & Chief Executive Officer Santos Da Silva Jorge , and Chief Financial Officer Matthias Bodenstedt .

MoonLake Immunotherapeutics (MLTX) Insider Trades Summary

Over the past 18 months, Bihua Chen made 1 insider transaction in MoonLake Immunotherapeutics (MLTX) with a net sale of 6,499,978. Other recent insider transactions involving MoonLake Immunotherapeutics (MLTX) include a net sale of 466,261 shares made by Kristian Reich , a net sale of 150,000 shares made by Matthias Bodenstedt , and a net sale of 500,000 shares made by Santos Da Silva Jorge .

In summary, during the past 3 months, insiders sold 470,349 shares of MoonLake Immunotherapeutics (MLTX) in total and bought 0 shares, with a net sale of 470,349 shares. During the past 18 months, 11,400,609 shares of MoonLake Immunotherapeutics (MLTX) were sold and 10,870 shares were bought by its insiders, resulting in a net sale of 11,389,739 shares.

MoonLake Immunotherapeutics (MLTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

MoonLake Immunotherapeutics Insider Transactions

No Available Data

What does Monte Rosa Therapeutics Inc do?

Who are the key executives at Monte Rosa Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Monte Rosa Therapeutics Inc. Other key executives at Monte Rosa Therapeutics Inc include director & See Remarks Markus Warmuth , Chief Operating Officer Jennifer Champoux , and Chief Technology Officer Sharon Townson .

Monte Rosa Therapeutics Inc (GLUE) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Monte Rosa Therapeutics Inc (GLUE). Other recent insider transactions involving Monte Rosa Therapeutics Inc (GLUE) include a net sale of 49,500 shares made by Markus Warmuth , a net sale of 15,682 shares made by Jennifer Champoux , and a net sale of 65,596 shares made by Filip Janku .

In summary, during the past 3 months, insiders sold 93,454 shares of Monte Rosa Therapeutics Inc (GLUE) in total and bought 0 shares, with a net sale of 93,454 shares. During the past 18 months, 209,873 shares of Monte Rosa Therapeutics Inc (GLUE) were sold and 10,000 shares were bought by its insiders, resulting in a net sale of 199,873 shares.

Monte Rosa Therapeutics Inc (GLUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Monte Rosa Therapeutics Inc Insider Transactions

No Available Data

What does BioAtla Inc do?

Who are the key executives at BioAtla Inc?

Bihua Chen is the director & 10 percent owner of BioAtla Inc. Other key executives at BioAtla Inc include director & 10 percent owner & Chief Executive Officer Short Jay M Phd , See Remarks Christian Vasquez , and director & President Scott Andrew Smith .

BioAtla Inc (BCAB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BioAtla Inc (BCAB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BioAtla Inc (BCAB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BioAtla Inc (BCAB)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioAtla Inc Insider Transactions

No Available Data

What does Vigil Neuroscience Inc do?

Who are the key executives at Vigil Neuroscience Inc?

Bihua Chen is the 10 percent owner of Vigil Neuroscience Inc. Other key executives at Vigil Neuroscience Inc include director & President and CEO Ivana Magovcevic-liebisch , Chief Medical Officer Petra Kaufmann , and Chief Medical Officer Christopher Silber .

Vigil Neuroscience Inc (VIGL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Vigil Neuroscience Inc (VIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vigil Neuroscience Inc (VIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Vigil Neuroscience Inc (VIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vigil Neuroscience Inc Insider Transactions

No Available Data

What does Biomea Fusion Inc do?

Who are the key executives at Biomea Fusion Inc?

Bihua Chen is the director & 10 percent owner of Biomea Fusion Inc. Other key executives at Biomea Fusion Inc include director & 10 percent owner & President and COO Rainer M Erdtmann , Chief Financial Officer Franco Valle , and Chief Medical Officer Juan Pablo Frias .

Biomea Fusion Inc (BMEA) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Biomea Fusion Inc (BMEA). Other recent insider transactions involving Biomea Fusion Inc (BMEA) include a net purchase of 80,000 shares made by Rainer M Erdtmann , and a net purchase of 100,000 shares made by Hitchcock Michael J.m. .

In summary, during the past 3 months, insiders sold 0 shares of Biomea Fusion Inc (BMEA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Biomea Fusion Inc (BMEA) were sold and 180,000 shares were bought by its insiders, resulting in a net purchase of 180,000 shares.

Biomea Fusion Inc (BMEA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Biomea Fusion Inc Insider Transactions

No Available Data

What does Verve Therapeutics Inc do?

Who are the key executives at Verve Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Verve Therapeutics Inc. Other key executives at Verve Therapeutics Inc include director & 10 percent owner & Chief Executive Officer Sekar Kathiresan , Chief Financial Officer Allison Dorval , and See Remarks Andrew D. Ashe .

Verve Therapeutics Inc (VERV) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Verve Therapeutics Inc (VERV). Other recent insider transactions involving Verve Therapeutics Inc (VERV) include a net sale of 9,822 shares made by Sekar Kathiresan , a net sale of 3,350 shares made by Allison Dorval , and a net sale of 3,235 shares made by Jason Politi .

In summary, during the past 3 months, insiders sold 0 shares of Verve Therapeutics Inc (VERV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 24,054 shares of Verve Therapeutics Inc (VERV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 24,054 shares.

Verve Therapeutics Inc (VERV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verve Therapeutics Inc Insider Transactions

No Available Data

What does Ventyx Biosciences Inc do?

Who are the key executives at Ventyx Biosciences Inc?

Bihua Chen is the 10 percent owner of Ventyx Biosciences Inc. Other key executives at Ventyx Biosciences Inc include director & Chief Executive Officer Raju Mohan , Chief Scientific Officer John Nuss , and Chief Medical Officer Mark S Forman .

Ventyx Biosciences Inc (VTYX) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Ventyx Biosciences Inc (VTYX). Other recent insider transactions involving Ventyx Biosciences Inc (VTYX) include a net sale of 14,562 shares made by John Nuss , and a net sale of 47,345 shares made by Raju Mohan .

In summary, during the past 3 months, insiders sold 0 shares of Ventyx Biosciences Inc (VTYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 61,907 shares of Ventyx Biosciences Inc (VTYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 61,907 shares.

Ventyx Biosciences Inc (VTYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ventyx Biosciences Inc Insider Transactions

No Available Data

What does Tyra Biosciences Inc do?

Who are the key executives at Tyra Biosciences Inc?

Bihua Chen is the 10 percent owner of Tyra Biosciences Inc. Other key executives at Tyra Biosciences Inc include Vice President & Finance (PAO) Yuliya Rueb , Chief Operating Officer Daniel Bensen , and director & 10 percent owner Robert J More .

Tyra Biosciences Inc (TYRA) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Tyra Biosciences Inc (TYRA). Other recent insider transactions involving Tyra Biosciences Inc (TYRA) include a net sale of 281,000 shares made by Daniel Bensen , a net purchase of 1,561,335 shares made by Ra Capital Healthcare Fund Lp , and a net sale of 75,687 shares made by Gilla Kaplan .

In summary, during the past 3 months, insiders sold 0 shares of Tyra Biosciences Inc (TYRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 613,558 shares of Tyra Biosciences Inc (TYRA) were sold and 1,561,335 shares were bought by its insiders, resulting in a net purchase of 947,777 shares.

Tyra Biosciences Inc (TYRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tyra Biosciences Inc Insider Transactions

No Available Data

What does Kineta Inc do?

Who are the key executives at Kineta Inc?

Bihua Chen is the director & 10 percent owner of Kineta Inc. Other key executives at Kineta Inc include director & Chief Executive Officer Shawn Iadonato , President Craig W. Philips , and General Counsel Pauline Kenny .

Kineta Inc (KANT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kineta Inc (KANT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kineta Inc (KANT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kineta Inc (KANT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kineta Inc Insider Transactions

No Available Data

What does Ambrx Biopharma Inc do?

Who are the key executives at Ambrx Biopharma Inc?

Bihua Chen is the 10 percent owner of Ambrx Biopharma Inc. Other key executives at Ambrx Biopharma Inc include 10 percent owner Cormorant Asset Management, Lp , Chief Financial Officer Sonja Nelson , and director & President and CEO Daniel J. O'connor .

Ambrx Biopharma Inc (AMAM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ambrx Biopharma Inc (AMAM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ambrx Biopharma Inc (AMAM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ambrx Biopharma Inc (AMAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ambrx Biopharma Inc Insider Transactions

No Available Data

What does GreenLight Biosciences Holdings PBC do?

Who are the key executives at GreenLight Biosciences Holdings PBC?

Bihua Chen is the other: See below of GreenLight Biosciences Holdings PBC. Other key executives at GreenLight Biosciences Holdings PBC include other: See remarks Mls Capital Fund Ii Lp , other: Member of 10% owner group Marta Ortega-valle , and other: Member of 13D Group Montealegre Lacayo Jaime Javier .

GreenLight Biosciences Holdings PBC (GRNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of GreenLight Biosciences Holdings PBC (GRNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of GreenLight Biosciences Holdings PBC (GRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

GreenLight Biosciences Holdings PBC (GRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

GreenLight Biosciences Holdings PBC Insider Transactions

No Available Data

What does Environmental Impact Acquisition Corp do?

Who are the key executives at Environmental Impact Acquisition Corp?

Bihua Chen is the other: See below of Environmental Impact Acquisition Corp. Other key executives at Environmental Impact Acquisition Corp include director & 10 percent owner Matthew Allen Walker , other: Member of 10% owner group Marta Ortega-valle , and other: Member of 13D Group Montealegre Lacayo Jaime Javier .

Environmental Impact Acquisition Corp (ENVIU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Environmental Impact Acquisition Corp (ENVIU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Environmental Impact Acquisition Corp (ENVIU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Environmental Impact Acquisition Corp (ENVIU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Environmental Impact Acquisition Corp Insider Transactions

No Available Data

What does Ambrx Biopharma Inc do?

Who are the key executives at Ambrx Biopharma Inc?

Bihua Chen is the 10 percent owner of Ambrx Biopharma Inc. Other key executives at Ambrx Biopharma Inc include Chief Financial Officer Sonja Nelson , director & President and CEO Daniel J. O'connor , and 10 percent owner Cormorant Asset Management, Lp .

Ambrx Biopharma Inc (AMAM) Insider Trades Summary

Ambrx Biopharma Inc (AMAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ambrx Biopharma Inc Insider Transactions

No Available Data

What does OnKure Therapeutics Inc do?

Who are the key executives at OnKure Therapeutics Inc?

Bihua Chen is the 10 percent owner of OnKure Therapeutics Inc. Other key executives at OnKure Therapeutics Inc include director & President and CEO Nicholas A Saccomano , Chief Financial Officer Jason A. Leverone , and 10 percent owner Access Industries Holdings Llc .

OnKure Therapeutics Inc (OKUR) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in OnKure Therapeutics Inc (OKUR). Other recent insider transactions involving OnKure Therapeutics Inc (OKUR) include a net sale of 4,634 shares made by Jason A. Leverone , a net sale of 1,309 shares made by Nicholas A Saccomano , and a net sale of 1,837,739 shares made by Cormorant Global Healthcare Master Fund, Lp .

In summary, during the past 3 months, insiders sold 389 shares of OnKure Therapeutics Inc (OKUR) in total and bought 0 shares, with a net sale of 389 shares. During the past 18 months, 1,843,682 shares of OnKure Therapeutics Inc (OKUR) were sold and 1,400,000 shares were bought by its insiders, resulting in a net sale of 443,682 shares.

OnKure Therapeutics Inc (OKUR)'s detailed insider trading history can be found in Insider Trading Tracker table.

OnKure Therapeutics Inc Insider Transactions

No Available Data

What does EyePoint Inc do?

Who are the key executives at EyePoint Inc?

Bihua Chen is the 10 percent owner of EyePoint Inc. Other key executives at EyePoint Inc include Chief Medical Officer Ramiro Ribeiro , director & President and CEO Nancy Lurker , and 10 percent owner Cormorant Global Healthcare Master Fund, Lp .

EyePoint Inc (EYPT) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in EyePoint Inc (EYPT). Other recent insider transactions involving EyePoint Inc (EYPT) include a net sale of 57,453 shares made by Ramiro Ribeiro , a net purchase of 30,600 shares made by Karen L. Zaderej , and a net sale of 10,000 shares made by Nancy Lurker .

In summary, during the past 3 months, insiders sold 4,875 shares of EyePoint Inc (EYPT) in total and bought 10,600 shares, with a net purchase of 5,725 shares. During the past 18 months, 127,453 shares of EyePoint Inc (EYPT) were sold and 32,100 shares were bought by its insiders, resulting in a net sale of 95,353 shares.

EyePoint Inc (EYPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

EyePoint Inc Insider Transactions

No Available Data

What does Corbus Pharmaceuticals Holdings Inc do?

Who are the key executives at Corbus Pharmaceuticals Holdings Inc?

Bihua Chen is the 10 percent owner of Corbus Pharmaceuticals Holdings Inc. Other key executives at Corbus Pharmaceuticals Holdings Inc include Chief Business Officer Nishant C Saxena , Chief Financial Officer Sean F. Moran , and director & Chief Executive Officer Yuval Cohen .

Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Corbus Pharmaceuticals Holdings Inc (CRBP). Other recent insider transactions involving Corbus Pharmaceuticals Holdings Inc (CRBP) include a net sale of 58,504 shares made by Yuval Cohen , a net sale of 29,682 shares made by Sean F. Moran , and a net sale of 4,864 shares made by Anne Altmeyer .

In summary, during the past 3 months, insiders sold 29,000 shares of Corbus Pharmaceuticals Holdings Inc (CRBP) in total and bought 2,600 shares, with a net sale of 26,400 shares. During the past 18 months, 145,332 shares of Corbus Pharmaceuticals Holdings Inc (CRBP) were sold and 16,100 shares were bought by its insiders, resulting in a net sale of 129,232 shares.

Corbus Pharmaceuticals Holdings Inc (CRBP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Corbus Pharmaceuticals Holdings Inc Insider Transactions

No Available Data

What does Bioage Labs Inc do?

Who are the key executives at Bioage Labs Inc?

Bihua Chen is the 10 percent owner of Bioage Labs Inc. Other key executives at Bioage Labs Inc include Principal Accounting Officer Shane Barton , Chief Medical Officer Paul D Rubin , and Chief Financial Officer Goldstein Dov A Md .

Bioage Labs Inc (BIOA) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Bioage Labs Inc (BIOA). Other recent insider transactions involving Bioage Labs Inc (BIOA) include a net sale of 118,016 shares made by Paul D Rubin , a net sale of 233,107 shares made by Kristen Fortney , and a net sale of 62,566 shares made by Shane Barton .

In summary, during the past 3 months, insiders sold 62,566 shares of Bioage Labs Inc (BIOA) in total and bought 0 shares, with a net sale of 62,566 shares. During the past 18 months, 440,689 shares of Bioage Labs Inc (BIOA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 440,689 shares.

Bioage Labs Inc (BIOA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bioage Labs Inc Insider Transactions

No Available Data

What does Aardvark Therapeutics Inc do?

Who are the key executives at Aardvark Therapeutics Inc?

Bihua Chen is the 10 percent owner of Aardvark Therapeutics Inc. Other key executives at Aardvark Therapeutics Inc include director & 10 percent owner & Chief Executive Officer Tien-li Lee , Chief Financial Officer Nelson Sun , and 10 percent owner Cormorant Asset Management, Lp .

Aardvark Therapeutics Inc (AARD) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Aardvark Therapeutics Inc (AARD). Other recent insider transactions involving Aardvark Therapeutics Inc (AARD) include a net purchase of 37,000 shares made by Tien-li Lee , and a net purchase of 9,000 shares made by Nelson Sun .

In summary, during the past 3 months, insiders sold 0 shares of Aardvark Therapeutics Inc (AARD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aardvark Therapeutics Inc (AARD) were sold and 46,000 shares were bought by its insiders, resulting in a net purchase of 46,000 shares.

Aardvark Therapeutics Inc (AARD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aardvark Therapeutics Inc Insider Transactions

No Available Data

What does Jade Biosciences Inc do?

Who are the key executives at Jade Biosciences Inc?

Bihua Chen is the 10 percent owner of Jade Biosciences Inc. Other key executives at Jade Biosciences Inc include director & 10 percent owner Fairmount Healthcare Co-invest Iv L.p. , Chief Financial Officer Bradford D. Dahms , and Chief Medical Officer Hetal Kocinsky .

Jade Biosciences Inc (JBIO) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Jade Biosciences Inc (JBIO). Other recent insider transactions involving Jade Biosciences Inc (JBIO) include a net purchase of 6,000 shares made by Tom Frohlich ,

In summary, during the past 3 months, insiders sold 0 shares of Jade Biosciences Inc (JBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Jade Biosciences Inc (JBIO) were sold and 6,000 shares were bought by its insiders, resulting in a net purchase of 6,000 shares.

Jade Biosciences Inc (JBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Jade Biosciences Inc Insider Transactions

No Available Data

What does Bright Minds Biosciences Inc do?

Who are the key executives at Bright Minds Biosciences Inc?

Bihua Chen is the 10 percent owner of Bright Minds Biosciences Inc. Other key executives at Bright Minds Biosciences Inc include 10 percent owner Cormorant Asset Management, Lp , and 10 percent owner Cormorant Global Healthcare Master Fund, Lp .

Bright Minds Biosciences Inc (DRUG) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Bright Minds Biosciences Inc (DRUG). Other recent insider transactions involving Bright Minds Biosciences Inc (DRUG) include a net sale of 109,331 shares made by Cormorant Asset Management, Lp ,

In summary, during the past 3 months, insiders sold 0 shares of Bright Minds Biosciences Inc (DRUG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 109,331 shares of Bright Minds Biosciences Inc (DRUG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 109,331 shares.

Bright Minds Biosciences Inc (DRUG)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bright Minds Biosciences Inc Insider Transactions

No Available Data

What does BridgeBio Oncology Therapeutics Inc do?

Who are the key executives at BridgeBio Oncology Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of BridgeBio Oncology Therapeutics Inc. Other key executives at BridgeBio Oncology Therapeutics Inc include Principal Accounting Officer Marc Cobo , COO & Principal Financial Ofcr Idan Elmelech , and 10 percent owner Bridgebio Pharma, Inc. .

BridgeBio Oncology Therapeutics Inc (BBOT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BridgeBio Oncology Therapeutics Inc (BBOT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BridgeBio Oncology Therapeutics Inc (BBOT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BridgeBio Oncology Therapeutics Inc (BBOT)'s detailed insider trading history can be found in Insider Trading Tracker table.

BridgeBio Oncology Therapeutics Inc Insider Transactions

No Available Data

What does Helix Acquisition Corp III do?

Who are the key executives at Helix Acquisition Corp III?

Bihua Chen is the director & 10 percent owner & Chairperson and CEO of Helix Acquisition Corp III. Other key executives at Helix Acquisition Corp III include CFO & COO Caleb Tripp , Chief Legal Officer Nebojsa Obradovic , and 10 percent owner Helix Holdings Iii Llc .

Helix Acquisition Corp III (HLXC) Insider Trades Summary

Over the past 18 months, Bihua Chen made 1 insider transaction in Helix Acquisition Corp III (HLXC) with a net purchase of 800,000.

In summary, during the past 3 months, insiders sold 0 shares of Helix Acquisition Corp III (HLXC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Helix Acquisition Corp III (HLXC) were sold and 800,000 shares were bought by its insiders, resulting in a net purchase of 800,000 shares.

Helix Acquisition Corp III (HLXC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Helix Acquisition Corp III Insider Transactions

No Available Data

What does BlossomHill Therapeutics Inc do?

Who are the key executives at BlossomHill Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of BlossomHill Therapeutics Inc. Other key executives at BlossomHill Therapeutics Inc include 10 percent owner Cormorant Asset Management, Lp , 10 percent owner Cormorant Global Healthcare Master Fund, Lp , and Chief Financial Officer Jason A Keyes .

BlossomHill Therapeutics Inc (BLSM) Insider Trades Summary

Over the past 18 months, Bihua Chen made 1 insider transaction in BlossomHill Therapeutics Inc (BLSM) with a net purchase of 312,500. Other recent insider transactions involving BlossomHill Therapeutics Inc (BLSM) include a net purchase of 625,000 shares made by Orbimed Advisors Llc , a net purchase of 625,000 shares made by Carl L Gordon , and a net purchase of 6,000 shares made by John P. Schmid .

In summary, during the past 3 months, insiders sold 0 shares of BlossomHill Therapeutics Inc (BLSM) in total and bought 1,573,900 shares, with a net purchase of 1,573,900 shares. During the past 18 months, 0 shares of BlossomHill Therapeutics Inc (BLSM) were sold and 1,573,900 shares were bought by its insiders, resulting in a net purchase of 1,573,900 shares.

BlossomHill Therapeutics Inc (BLSM)'s detailed insider trading history can be found in Insider Trading Tracker table.

BlossomHill Therapeutics Inc Insider Transactions

No Available Data

Bihua Chen Mailing Address

Above is the net worth, insider trading, and ownership report for Bihua Chen. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Bihua Chen's mailing address is: Boston Ma 02116.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.